The creation of each new biotechnology enables a tool, a therapy, or a diagnostic: a molecule, a protein, an app, a platform. And the process underneath isn't just complex in the science and engineering of it, but in the go to market.

So who are the stakeholders in this process? In this podcast (which was originally recorded as a video), a16z bio fund general partners Jorge Conde and Vijay Pande give a quick hallway-conversation style overview on the stakeholders -- as well as what the process is from inception to approval to market; how do go-to-market models differ; and what should founders know at the beginning of each path.

Stay Updated:

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Podcast on Spotify

Listen to the a16z Podcast on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.